US5747469A
(en)
|
1991-03-06 |
1998-05-05 |
Board Of Regents, The University Of Texas System |
Methods and compositions comprising DNA damaging agents and p53
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
CA2108144A1
(en)
|
1991-03-06 |
1992-09-07 |
Jack A. Roth |
Methods and compositions for the selective inhibition of gene expression
|
IL113052A0
(en)
|
1994-03-23 |
1995-06-29 |
Rhone Poulenc Rorer Sa |
Recombinant viruses, their preparation and their use in gene therapy
|
EP1548118A2
(en)
|
1994-06-10 |
2005-06-29 |
Genvec, Inc. |
Complementary adenoviral vector systems and cell lines
|
FR2722507B1
(fr)
*
|
1994-07-12 |
1996-08-14 |
Rhone Poulenc Rorer Sa |
Adenovirus comportant un gene codant pour une no synthase
|
FR2724320B1
(fr)
*
|
1994-09-13 |
1996-12-20 |
Transgene Sa |
Nouvel implant pour le traitement des maladies acquises
|
FR2725213B1
(fr)
*
|
1994-10-04 |
1996-11-08 |
Rhone Poulenc Rorer Sa |
Vecteurs viraux et utilisation en therapie genique
|
FR2726285B1
(fr)
*
|
1994-10-28 |
1996-11-29 |
Centre Nat Rech Scient |
Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
|
FR2727689A1
(fr)
|
1994-12-01 |
1996-06-07 |
Transgene Sa |
Nouveau procede de preparation d'un vecteur viral
|
CN1136920C
(zh)
|
1995-02-28 |
2004-02-04 |
加利福尼亚大学董事会 |
基因转移介导的血管形成疗法
|
US6752987B1
(en)
|
1995-02-28 |
2004-06-22 |
The Regents Of The University Of California |
Adenovirus encoding human adenylylcyclase (AC) VI
|
FR2731710B1
(fr)
*
|
1995-03-14 |
1997-04-30 |
Rhone Poulenc Rorer Sa |
Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique
|
FR2732357B1
(fr)
*
|
1995-03-31 |
1997-04-30 |
Rhone Poulenc Rorer Sa |
Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
|
US5698202A
(en)
*
|
1995-06-05 |
1997-12-16 |
The Wistar Institute Of Anatomy & Biology |
Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
|
US6281010B1
(en)
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
AU6261696A
(en)
|
1995-06-05 |
1996-12-24 |
Trustees Of The University Of Pennsylvania, The |
A replication-defective adenovirus human type 5 recombinant as a vaccine carrier
|
US5756283A
(en)
*
|
1995-06-05 |
1998-05-26 |
The Trustees Of The University Of Pennsylvania |
Method for improved production of recombinant adeno-associated viruses for gene therapy
|
US6265212B1
(en)
|
1995-06-15 |
2001-07-24 |
Introgene B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US6783980B2
(en)
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
PT833934E
(pt)
|
1995-06-15 |
2005-02-28 |
Crucell Holland Bv |
Sistemas de empacotamento para adenovivrus recombinente humano destinados a terapia genetica
|
AUPN477695A0
(en)
*
|
1995-08-14 |
1995-09-07 |
Commonwealth Scientific And Industrial Research Organisation |
Gene therapy
|
FR2740344B1
(fr)
*
|
1995-10-31 |
1997-11-21 |
Rhone Poulenc Rorer Sa |
Application de la proteine gax au traitement de cancers
|
JP2002512501A
(ja)
*
|
1996-07-03 |
2002-04-23 |
メリアル インコーポレイテッド |
外来性dnaを含む組換えイヌアデノウィルス(cav)
|
AU4255397A
(en)
*
|
1996-09-06 |
1998-03-26 |
Trustees Of The University Of Pennsylvania, The |
Chimpanzee adenovirus vectors
|
CA2288306A1
(en)
|
1997-04-28 |
1998-11-05 |
Rhone-Poulenc Rorer S.A. |
Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
|
WO1999019466A2
(en)
|
1997-10-14 |
1999-04-22 |
Darwin Molecular Corporation |
Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
|
US6875606B1
(en)
|
1997-10-23 |
2005-04-05 |
The United States Of America As Represented By The Department Of Veterans Affairs |
Human α-7 nicotinic receptor promoter
|
US6653088B1
(en)
|
1997-10-24 |
2003-11-25 |
Aventis Pharma S.A. |
Interaction test for the investigation of inhibitory molecules of the interaction between a presenilin and the β-amyloid peptide
|
DK1049767T3
(da)
|
1998-01-08 |
2005-09-19 |
Aventis Pharma Inc |
En transgen kanin, der udtrykker et funktionelt humant lipoprotein(A)
|
US6670188B1
(en)
|
1998-04-24 |
2003-12-30 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US6225456B1
(en)
|
1998-05-07 |
2001-05-01 |
University Technololy Corporation |
Ras suppressor SUR-5
|
US6506889B1
(en)
|
1998-05-19 |
2003-01-14 |
University Technology Corporation |
Ras suppressor SUR-8 and related compositions and methods
|
CA2339409A1
(en)
|
1998-08-11 |
2000-02-24 |
Darwin Discovery Ltd. |
Identification of the gene causing the mouse scurfy phenotype and its human ortholog
|
IL143266A0
(en)
|
1998-11-27 |
2002-04-21 |
Darwin Discovery Ltd |
Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
US7063850B1
(en)
|
1998-12-22 |
2006-06-20 |
University Of Tennessee Research Foundation |
Protective antigen of group A Streptococci
|
US6441156B1
(en)
|
1998-12-30 |
2002-08-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Calcium channel compositions and methods of use thereof
|
FR2794771B1
(fr)
*
|
1999-06-11 |
2001-08-10 |
Aventis Pharma Sa |
Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
|
FR2799472B1
(fr)
|
1999-10-07 |
2004-07-16 |
Aventis Pharma Sa |
Preparation d'adenovirus recombinants et de banques adenovirales
|
AU2460001A
(en)
*
|
1999-12-27 |
2001-07-09 |
Regents Of The University Of California, The |
Gene therapy for congestive heart failure
|
EP1248803B1
(en)
|
2000-01-12 |
2010-05-05 |
Yale University |
Nogo receptor-mediated blockade of axonal growth
|
EP1267839B1
(en)
|
2000-03-24 |
2007-10-03 |
Biosphere Medical, Inc. |
Microspheres for active embolization
|
GB0018307D0
(en)
|
2000-07-26 |
2000-09-13 |
Aventis Pharm Prod Inc |
Polypeptides
|
US7060442B2
(en)
|
2000-10-30 |
2006-06-13 |
Regents Of The University Of Michigan |
Modulators on Nod2 signaling
|
MXPA03005386A
(es)
|
2000-12-28 |
2004-04-20 |
Wyeth Corp |
Proteina protectora recombinante de streptococcus pneumoniae.
|
DE60228477D1
(de)
|
2001-05-08 |
2008-10-02 |
Darwin Molecular Corp |
Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins
|
AUPR518501A0
(en)
|
2001-05-22 |
2001-06-14 |
Unisearch Limited |
Yin yang-1
|
AU2002325346A1
(en)
|
2001-07-05 |
2003-01-21 |
Aventis Pharma S.A. |
Method of administration of a gene of interest to the heart and vasculature
|
US7582425B2
(en)
|
2001-09-21 |
2009-09-01 |
The Regents Of The University Of Michigan |
Atlastin
|
US7108975B2
(en)
|
2001-09-21 |
2006-09-19 |
Regents Of The University Of Michigan |
Atlastin
|
US20040023910A1
(en)
*
|
2001-09-28 |
2004-02-05 |
Zhiming Zhang |
Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
US6939959B2
(en)
|
2001-10-26 |
2005-09-06 |
Id Biomedical Corporation Of Washington |
Efficient protein expression system
|
WO2003049764A1
(en)
|
2001-12-12 |
2003-06-19 |
Fh Faulding & Co Limited |
Composition for viral preservation
|
US20030158112A1
(en)
|
2002-02-15 |
2003-08-21 |
Johns Hopkins University School Of Medicine |
Selective induction of apoptosis to treat ocular disease
|
NZ571508A
(en)
|
2002-05-24 |
2010-05-28 |
Schering Corp |
Neutralizing human anti-IGFR antibody
|
US7785608B2
(en)
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
FR2845395B1
(fr)
*
|
2002-10-08 |
2008-05-30 |
Agronomique Inst Nat Rech |
Vecteurs adenoviraux recombinants et leurs applications
|
WO2005020928A2
(en)
|
2003-08-29 |
2005-03-10 |
The Regents Of The University Of California |
Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
|
US7432057B2
(en)
|
2004-01-30 |
2008-10-07 |
Michigan State University |
Genetic test for PSE-susceptible turkeys
|
CN1997746B
(zh)
|
2004-05-26 |
2012-09-26 |
普西奥克瑟斯医疗有限公司 |
用于治疗癌症的嵌合腺病毒
|
US7604798B2
(en)
|
2004-07-15 |
2009-10-20 |
Northwestern University |
Methods and compositions for importing nucleic acids into cell nuclei
|
AU2005274948B2
(en)
|
2004-07-16 |
2011-09-22 |
Genvec, Inc. |
Vaccines against aids comprising CMV/R-nucleic acid constructs
|
EP2002003B1
(en)
|
2005-05-27 |
2015-12-30 |
Ospedale San Raffaele S.r.l. |
Gene vector comprising mi-rna
|
US9670244B2
(en)
|
2006-02-27 |
2017-06-06 |
The Regents Of The University Of California |
Oxysterol compounds and the hedgehog pathway
|
AU2007276793B2
(en)
|
2006-07-28 |
2014-01-16 |
Sanofi |
Composition and method for treatment of tumors
|
ES2388567T3
(es)
|
2006-10-19 |
2012-10-16 |
Csl Limited |
Anticuerpos anti-il-13r alfa 1 y usos de los mismos
|
EP2068921B1
(en)
|
2006-10-19 |
2014-07-09 |
CSL Limited |
High affinity antibody antagonists of interleukin-13 receptor alpha 1
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
US9526737B2
(en)
|
2007-12-03 |
2016-12-27 |
The Regents Of The University Of California |
Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling
|
AR074273A1
(es)
|
2008-11-05 |
2011-01-05 |
Wyeth Corp |
Composicion inmunigenica de multiples componentes para la prevencion de la enfermedad estreptococica beta-hemolitica bhs. uso. metodo
|
EP3115063A3
(en)
|
2008-12-03 |
2017-04-19 |
The John Hopkins University |
Galectin-3 and annexin-a2 as immunological target
|
EP2370579B1
(en)
*
|
2008-12-04 |
2017-03-29 |
CuRNA, Inc. |
Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
|
WO2010096561A1
(en)
|
2009-02-18 |
2010-08-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Synthetic hiv/siv gag proteins and uses thereof
|
CA2793521A1
(en)
|
2010-03-19 |
2011-09-22 |
University Of South Alabama |
Use of antisense gli1 for reducing the dosage of a therapeutic compound to treat needed to treat a cancer
|
CN107412251A
(zh)
*
|
2010-05-26 |
2017-12-01 |
库尔纳公司 |
通过抑制无调同源物1(atoh1)的天然反义转录物而治疗atoh1相关疾病
|
JP6023705B2
(ja)
*
|
2010-06-23 |
2016-11-09 |
カッパーアールエヌエー,インコーポレイテッド |
ナトリウムチャネル、電位依存性、αサブユニット(SCNA)に対する天然アンチセンス転写物の阻害によるSCNA関連疾患の治療
|
DK3831406T3
(da)
|
2010-08-23 |
2024-06-17 |
Wyeth Llc |
Stabile formuleringer af Neisseria-Meningitidis-RLP2086-antigener
|
CA2809758C
(en)
|
2010-09-10 |
2021-07-13 |
Wyeth Llc |
Non-lipidated variants of neisseria meningitidis orf2086 antigens
|
US9458456B2
(en)
|
2011-04-01 |
2016-10-04 |
University Of South Alabama |
Methods and compositions for the diagnosis, classification, and treatment of cancer
|
US9464291B2
(en)
|
2012-01-06 |
2016-10-11 |
University Of South Alabama |
Methods and compositions for the treatment of cancer
|
BR112014021658A2
(pt)
|
2012-03-09 |
2017-07-11 |
Pfizer |
composições de neisseria meningitidis e métodos das mesmas
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
RU2632191C2
(ru)
|
2012-05-07 |
2017-10-03 |
Те Риджентс Оф Те Юниверсити Оф Калифорния |
Аналог оксистерола oxy133 индуцирует остеогенез и сигнальный путь hedgehog и ингибирует липогенез
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
EP2946016A4
(en)
*
|
2013-01-15 |
2016-11-23 |
Univ California |
ADENOVIRUS AND THEIR USE
|
WO2014136064A2
(en)
|
2013-03-08 |
2014-09-12 |
Pfizer Inc. |
Immunogenic fusion polypeptides
|
EP2968613B1
(en)
|
2013-03-11 |
2019-09-11 |
University of Florida Research Foundation, Inc. |
Delivery of card protein as therapy for occular inflammation
|
EP2991652A4
(en)
|
2013-05-02 |
2016-12-07 |
Univ California |
OSSEOUS BONE TARGETING AGENTS BASED ON OSTEOGENOUS OXOGENOUS WITH BONE SELECTIVITY
|
EP4098276A1
(en)
|
2013-09-08 |
2022-12-07 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
EA036414B1
(ru)
|
2013-10-25 |
2020-11-09 |
Псайоксус Терапьютикс Лимитед |
Онколитические аденовирусы, содержащие трансгены
|
EP3107939B1
(en)
|
2014-02-19 |
2020-06-17 |
University of Florida Research Foundation, Inc. |
Delivery of nrf2 as therapy for protection against reactive oxygen species
|
CA2951221A1
(en)
|
2014-06-17 |
2015-12-23 |
Nippon Shinyaku Co., Ltd. |
Antisense nucleic acids
|
EP3250279B1
(en)
|
2015-01-30 |
2020-08-19 |
The Regents of the University of California |
Spinal subpial gene delivery system
|
BR112017017460A2
(pt)
|
2015-02-19 |
2018-04-10 |
Pfizer Inc. |
composições de neisseria meningitidis e métodos das mesmas
|
EP3288573B1
(en)
|
2015-04-30 |
2020-02-12 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding a b7 protein
|
CN108289909A
(zh)
|
2015-10-19 |
2018-07-17 |
巴尔的摩马里兰大学 |
用于产生工程改造的人原代血液树突细胞系的方法
|
SG11201805136TA
(en)
|
2015-12-17 |
2018-07-30 |
Psioxus Therapeutics Ltd |
Group b adenovirus encoding an anti-tcr-complex antibody or fragment
|
CN108884022B
(zh)
|
2016-03-28 |
2022-01-28 |
加利福尼亚大学董事会 |
用于治疗神经元的过度兴奋的方法和组合物
|
US11560412B2
(en)
|
2016-04-01 |
2023-01-24 |
University Of Maryland, Baltimore |
Compositions comprising GRIM-19 therapeutics and methods of use
|
ES2885833T3
(es)
|
2016-04-20 |
2021-12-15 |
Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P |
Composición y métodos para potenciar la expresión génica de PKLR
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
SG11201901715UA
(en)
|
2016-08-29 |
2019-03-28 |
Psioxus Therapeutics Ltd |
Adenovirus armed with bispecific t cell engager (bite)
|
EA201990711A1
(ru)
|
2016-09-20 |
2019-09-30 |
Бёрингер Ингельхайм Ветмедика Гмбх |
Новый ehv сайт инсерции orf70
|
AR109540A1
(es)
|
2016-09-20 |
2018-12-19 |
Boehringer Ingelheim Vetmedica Gmbh |
Moléculas promotoras para expresar antígenos virales
|
EP3515504B1
(en)
|
2016-09-20 |
2023-07-12 |
Boehringer Ingelheim Vetmedica GmbH |
Canine adenovirus vectors
|
TW201823465A
(zh)
|
2016-09-20 |
2018-07-01 |
德商百靈佳殷格翰維美迪加股份有限公司 |
新穎豬流感疫苗
|
WO2018142280A2
(en)
|
2017-01-31 |
2018-08-09 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
CN111163810B
(zh)
|
2017-10-16 |
2024-09-10 |
能源环境和技术研究中心O.A.,M.P. |
用于递送pklr以治疗丙酮酸激酶缺乏症的慢病毒载体
|
TW202413649A
(zh)
|
2017-10-16 |
2024-04-01 |
美商航海家醫療公司 |
肌萎縮性脊髓側索硬化症(als)之治療
|
EP3697908A1
(en)
|
2017-10-16 |
2020-08-26 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
AU2018359420A1
(en)
|
2017-10-31 |
2020-06-04 |
Kalivir Immunotherapeutics, Inc. |
Platform oncolytic vector for systemic delivery
|
WO2020010035A1
(en)
|
2018-07-02 |
2020-01-09 |
Voyager Therapeutics, Inc. |
Cannula system
|
CN112567035A
(zh)
|
2018-07-02 |
2021-03-26 |
沃雅戈治疗公司 |
肌萎缩侧索硬化症及脊髓相关病症的治疗
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
EP4192487A4
(en)
|
2020-08-07 |
2024-10-02 |
Spacecraft Seven Llc |
GENE THERAPY FOR PLAKOPHILIN-2 (PKP2) INVOLVING AAV VECTOR
|
TW202305125A
(zh)
|
2021-04-30 |
2023-02-01 |
美商凱立凡爾免疫治療股份有限公司 |
用於經修飾mhc表現之溶瘤病毒
|
CA3234811A1
(en)
|
2021-10-20 |
2023-04-27 |
Steven Goldman |
Rejuvenation treatment of age-related white matter loss
|
US20230270818A1
(en)
|
2021-11-02 |
2023-08-31 |
University Of Rochester |
Tcf7l2 mediated remyelination in the brain
|
WO2024091824A1
(en)
|
2022-10-26 |
2024-05-02 |
Ada Forsyth Institute, Inc. |
Differentiation and reprogramming of chondrocyte
|
WO2024163747A2
(en)
|
2023-02-02 |
2024-08-08 |
University Of Rochester |
Competitive replacement of glial cells
|